SeaCrest Wealth Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,357
Closed -$213K – 574
2026
Q2
$213K Buy
+1,357
New +$203K 0.02% 511
2025
Q3
– Sell
-2,027
Closed -$245K – 662
2025
Q2
$245K Sell
2,027
-206
-9% -$23.2K 0.03% 509
2025
Q1
$249K Sell
2,233
-38
-2% -$4.04K 0.03% 551
2024
Q4
$221K Buy
+2,271
New +$242K 0.02% 594
2024
Q1
– Sell
-2,139
Closed -$227K – 645
2023
Q4
$227K Sell
2,139
-653
-23% -$63K 0.03% 541
2023
Q3
$284K Buy
2,792
+314
+13% +$31.9K 0.04% 475
2023
Q2
$250K Sell
2,478
-235
-9% -$23.5K 0.03% 516
2023
Q1
$250K Buy
2,713
+334
+14% +$29.2K 0.03% 519
2022
Q4
$216K Buy
+2,379
New +$200K 0.03% 538
2022
Q3
– Sell
-2,212
Closed -$187K – 1197
2022
Q2
$187K Buy
+2,212
New +$194K 0.02% 630
2021
Q1
– Sell
-2,174
Closed -$205K – 674
2020
Q4
$205K Buy
+2,174
New +$190K 0.03% 561
2019
Q2
– Sell
-1,834
Closed -$158K – 1402
2019
Q1
$158K Sell
1,834
-174
-9% -$14K 0.03% 541
2018
Q4
$154K Buy
2,008
+76
+4% +$5.92K 0.03% 505
2018
Q3
$149K Hold
1,932
– – 0.03% 612
2018
Q2
$131K Buy
1,932
+287
+17% +$19.8K 0.02% 637
2018
Q1
$119K Hold
1,645
– – 0.02% 647
2017
Q4
$124K Buy
+1,645
New +$124K 0.02% 632

Other funds holding NVS

SeaCrest Wealth Management's NVS Position: Q3 2026 in Review

SeaCrest Wealth Management sold out of Novartis (NVS) in Q3 2026, closing a stake of 1,357 shares — an estimated $213K sold.

SeaCrest Wealth Management first reported a position in NVS in Q4 2017 and held it in 17 quarters. The position peaked at $284K in Q3 2023. 1,370 funds tracked by Wall St. Rank hold NVS as of Q3 2026.

  • SeaCrest Wealth Management reported no remaining Novartis position as of Q3 2026 after selling out during the quarter.
  • SeaCrest Wealth Management sold 1,357 Novartis shares in Q3 2026, an estimated $213K.
  • SeaCrest Wealth Management first reported a position in Novartis in Q4 2017 and held it in 17 quarters.
  • SeaCrest Wealth Management's Novartis position peaked at $284K in Q3 2023.
  • 1,370 funds tracked by Wall St. Rank held Novartis as of Q3 2026.

Based on SeaCrest Wealth Management's 13F filing for Q3 2026, filed 21 Oct 2026.